The Team

The Co-Founders

With combined operational leadership, clinical translation expertise, and physics-informed pathway-guided AI drug discovery to deliver selective candidates with improved safety and efficacy.

Yuan Liu, PhD
Co-Founder/Chairman, CSO

Pharma leader with 30+ years of experience spanning all phases of drug development, including contributions to landmark approvals such as Tafinlar/Mekinist, Votrient, and Ibrance.

Expert in precision medicine, biomarker strategy, ctDNA analytics, and clinical trial design, with 50+ publications in journals including Nature and the Journal of Clinical Oncology, and a distinguished presence at ASCO, AACR, and ESMO.

Peihong Tang, PhD
Co-Founder/Director, CEO

Established biotech operator who led R&D and drug development programs in neurology and oncology at Global Biolife Inc. later acquired by a NYSE-listed firm.

Earlier process development experience at Merck on blockbuster drugs Nexium and Prilosec.

Columbia PhD, and co-inventorship on multiple patents, executive training at Wharton management certificate program.

Yuhong Wang, MS
Co-Founder/Director, CTO

Principal Informatics Scientist from NIH with deep expertise in AI/ML, cheminformatics, and large-scale biological data systems.

Credited with developing 20+ ADMET machine-learning models, the generative AI Retro Drug Design paradigm.

~85 publications in top-tier journals, including Science, Nature, and PNAS